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Therapeutic vaccines, when used alone or in combination therapy with antileishmanial drugs, may have
an important place in the control of a variety of forms of human leishmaniasis. Here, we describe the
development of an adenovirus-based vaccine (Ad5-KH) comprising a synthetic haspb gene linked to a kmp11
gene via a viral 2A sequence. In nonvaccinated Leishmania donovani–infected BALB/c mice, HASPB- and
KMP11-speciﬁc CD8
1 T cell responses were undetectable, although IgG1 and IgG2a antibodies were evident.
After therapeutic vaccination, antibody responses were boosted, and IFNc
1CD8
1 T cell responses, particularly
to HASPB, became apparent. A single vaccination with Ad5-KH inhibited splenic parasite growth by 66%,
a level of efﬁcacy comparable to that observed in early stage testing of clinically approved antileishmanial drugs
in this model. These studies indicate the usefulness of adenoviral vectors to deliver leishmanial antigens in
a potent and host protective manner to animals with existing L. donovani infection.
The leishmaniases result from infection with protozoan
parasites of the genus Leishmania.S p r e a da c r o s s8 8
countries worldwide, the leishmaniases are regarded as
neglected tropical diseases [1, 2], a status reﬂected in
underfunding of drug and vaccine development pro-
grams [3]. Antimonial drugs remain the mainstay of
chemotherapy, although in the major endemic foci of
human visceral leishmaniasis (HVL) in India, drug re-
sistance has made these drugs of limited value. Only
amphotericin B, paromomycin, and miltefosine are
recognized alternatives [4]. Currently, there are no
vaccines licensed for use in humans [5].
Vaccination against leishmaniasis has long been held
to be achievable [6]. Self-cure provides long-lasting
protection and is the basis of leishmanization. Epi-
demiological evidence supports a degree of cross-
protection between Leishmania species. Prophylactic
immunization in rodents, dogs, and primates has been
partially successful using killed or attenuated parasites,
crude parasite extracts, recombinant proteins, DNA or
viral delivery, and peptide immunization [5]. To date,
vaccines have had poor efﬁcacy in clinical trials [7],
and concerns remain about the ability of experimental
models to predict protection against natural, sandﬂy-
transmitted infection [5]. The latter issue is of less
signiﬁcance for therapeutic vaccination and immu-
notherapy studies, and despite the immunosuppres-
sion associated with established disease, both clinical
and experimental data conﬁrm the potential of these
approaches [8–10]. Therapeutic vaccination may add
to the few tools currently available to treat patients,
shortening drug regimens and/or reducing dosage
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phylaxis, it may provide an attractive proposition for vaccine
development, given simpler clinical trial design [12].
Here, we report on the proof-of-concept stage of the de-
velopment of a therapeutic vaccine for HVL. We demonstrate
that 2 Leishmania antigens (HASPB and KMP11), delivered by
a single dose of a recombinant adenoviral vector, signiﬁcantly
reduce parasite burden in a stringent mouse model. Vaccination
was accompanied by newly detectable vaccine antigen-speciﬁc
CD8
1 T cell responses and boosting of pre-existing CD4
1
T cell–dependent antibody responses, and vaccine efﬁcacy
beneﬁted from the inherent adjuvant activity of the viral vector.
MATERIALS AND METHODS
Mice and Infections
Female BALB/c mice (Charles River) were maintained at the
University of York under speciﬁc pathogen-free conditions and
used at 6–12 weeks of age. L. donovani (MHOM/ET/67/L28/LV9)
was maintained in B6.RAG1
-/- mice, and amastigoteswere isolated
as described elsewhere [13]. Mice were infected intravenously with
2–3 3 10
7 amastigotes and were randomized to receive Ad5-KH
(see below) or Ad5-GFP (Vector BioLabs) in 20–50 lLs a l i n e
either subcutaneously at the base of the tail or intradermally in the
footpad. Mice were killed 10 days after vaccination, and spleens
were removed for assessment of parasite burden, as represented by
Leishman Donovan Units (LDU; representing the number of
amastigotes/1000 host cells 3 organ weight [13]) and for im-
munological analysis. Distribution of Ad-GFP was monitored by
ﬂuorescent stereomicroscopy [14]. All experiments were ap-
proved by the University of York Ethical Review Panel and
were performed under UK Home Ofﬁce license.
Recombinant Adenovirus
A synthetic haspb gene comprising the conserved N and C ter-
mini bordering 10 selected HASPB repeats was generated and
linked to the coding region of kmp11 by the tetravirus TaV 2A
sequence (RAEGRGSLLTCGDVEENPG; kindly provided by
Prof. M. Ryan, St. Andrews, UK). The ﬁnal sequence was back-
translated using Gene Designer DNA2.0 software with codons
optimized for human expression and selected to minimize
DNA repeat structures. The construct was ﬂanked by Kozak
sequence 5# of the ATG and a SV40-derived polyadenylation
sequence to improve translation initiation and allow mRNA
processing, respectively. The ﬁnal synthetic gene, called
huKMP11_HASPB_consensus, was synthesized under contract
by Geneart. The gene was inserted into an E1/E3 deleted Ad5
viral vector supplied by Vector Biolabs. The viral particle to
plaque-forming unit (pfu) ratio of the viruses used was 20–25:1.
Protein expression was conﬁrmed by Western blot using ly-
sates from P815 cells transduced with virus (multiplicity of
infection, 100:1) 24–36 hours earlier (data not shown, [15]).
ELISPOT Analysis
A truncated peptide library (PepSet) spanning the huKM-
P11_HASPB_consensusprotein using 11merswithanoverlapof
10 and offset of 1 was generated (Mimotopes). The 444 in-
dividualpeptidesets(eachcontaininga 11merplusits respective
truncated 10, 9, and 8 mers) were used in contiguous pools of
10 for initial epitope mapping studies or individually for ﬁne
mapping; 9-mer peptides were custom synthesized by Pro-
Immune. ELISPOT plates (Mabtech) were coated with anti-
IFNc overnight, washed, and then blocked with complete
RPMI 1640 (30 minutes at room temperature); 2.5 3 10
5
spleen cells or 10
5 puriﬁed CD8
1 T cells (with 2 3 10
5 naive
spleen cells) were seeded per well with or without peptides
(2 lg/mL). After overnight culture, plates were washed, and
numbers of IFN-c spot-forming cells were detected by conven-
tional methods. The detection limit for epitope-speciﬁc re-
sponses was conservatively estimated as 20 000 IFNc
1 CD8
1
Tcellsperuninfectedspleenand25 000IFNc
1 CD8
1 T cellsper
infected spleen.
Flow Cytometry and Cytokine Analysis
Splenocytes (2 3 10
6 cells/well) were restimulated in vitro for
7 hours at 37C in the presence of peptides (1 lg/mL) with
Brefeldin A (10 lg/mL) added for the last 4 hours. Cells were
surface stained (with CD3/CD90-PE-CY7, CD8 APC-Cy7/
APC-H7, and CD4-PERCP), ﬁxed (2% PFA, 10 minutes on
ice), washed (FACS buffer 1 0.5% saponin), and stained with
IFNc (XMG1.2)-PB, IL-10 (JES5-16E3)-APC, IL-2 (JES6-
5H4)-PE, and TNF (MP6-XT22)-FITC. Isotype control anti-
bodies were used to set markers for analysis and determination
of the frequency of cytokine producing cells (using a CyAn
analyser and Summit software; Beckman Coulter). The number
of peptide-speciﬁc cells per spleen was calculated from the
absolute number of CD3
1CD8
1 cells per spleen (obtained
from count beads) that produced IFNc after stimulation with
KMP11 or HASPB minus the number of IFNc-producing cells
observed in the no antigen control samples.
Generation of Recombinant Proteins
His-tagged recombinant huKMP11 and rhuHASPB_consensus
were puriﬁed by sequential nickel chelation chromatography
(HisTrap), anion exchangechromatography (HiTrapQ), and gel
ﬁltration (Superdex 200 16/60 or Superdex75 16/60, for HASPB
and KMP11, respectively) from French Press Escherichia coli
lysates clariﬁed by centrifugation and ﬁltration [15]. Puriﬁcations
w e r ep e r f o r m e do na nA K T A p u r i ﬁ e r 1 0 0 ,w i t hG EH e a l t h c a r e
columns. Proteins were analyzed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis and concentrated for storage.
Antibody Responses
Ninety-six–well Maxisorp plates (Nunc) were coated overnight
with 10 lg/mL of rhuKMP11 or rhuHASPB in carbonate buffer
(pH, 9.6). Plates were washed and blocked with PBS/0.05%
854 d JID 2012:205 (1 March) d Maroof et alTween/1% BSA for 2 hours at room temperature, and serum
samples were added in 2-fold serial dilutions (2 hours, room
temperature). Bound antibody was detected with peroxidase
goat anti-mouse IgG1 or IgG2a (2 hours, room temperature)
and quantiﬁed at 410 nm using ABTS substrate [13].
Statistical Analysis
With 8 mice per group, we calculated a 90% power to detect an
inhibition of parasite burden of 50%, with a signiﬁcance level of
0.05 (GraphPad Software).Data were analyzed by1-way analysis
of variance and Tukey’s Multiple Comparison Test, by paired
Student’s t test or by v
2 test, as appropriate.
RESULTS
Development of a Synthetic Vaccine Gene
HASPB contains multiple polymorphic 11–14 AA repeats
[15–17], and DNA sequencing has identiﬁed isolate-speciﬁc
HASPB variants, with different numbers, composition, and
relative order of repeats (Table 1). We designed a synthetic
haspb gene (HASPB_consensus) encoding the conserved N and
C termini bordering 10 of the repeats identiﬁed to date. To
include also a conserved protein, we produced a synthetic gene
with kmp11 (LinJ.35.2260/2270; Database version TriTrypDB
04.05.2011) and HASPB_consensus linked by a 2A sequence
derived from the tetravirus Thosea asigna virus (TaV) [18]
(Figure 1A). The fully synthetic gene with humanized codon
use was cloned into an E1/E3-deﬁcient adenovirus serotype 5
(Ad5) to generate the recombinant viral vaccine Ad5-huKM-
P11_HASPB_consensus (referred to as Ad5-KH).
Immunogenicity and CD8
1 T Cell Epitope Mapping of the
Response to Ad5-KH
To determine immunogenicity and map CD8
1 Tc e l le p i t o p e s ,
we used synthetic peptides that spanned the KH sequence in 20
AA segments. Uninfected BALB/c mice were vaccinated sub-
cutaneously with 10
8 pfu Ad5-KH, and after 10 days, ELISPOT
revealed a limited number of CD8
1 Tc e l le p i t o p e s( Figure 1B).
In HASPB, recognition was targeted to one 20mer region in the
conserved N-terminus: one spanning the last repeat region and
the conserved C-terminus and one spanning 2 repeats. For
KMP11, recognition was limited to a 30 amino acid stretch
(KMP1138–67). The location of these CD8
1 T cell epitopes is
indicated in Figure 1A and 1C.
We next evaluated whether route and dose inﬂuenced the
breadth and magnitude of the response (Figure 2). Increasing
the dose by 10-fold had little effect on epitope selection. How-
ever, whereas immunogenicity of the HASPB epitopes increased
by 2- and 4-fold, this was not the case for KMP11 responses
(Figure 2A and 2B). Altering the route of vaccination also
Table 1. Analysis of Repeat Type Frequency in Different Leishmania Species/Strains Causing Visceral Disease
HASPB Amino
Acid Repeats
Leishmania donovani Indian Isolates LV9
a
Leishmania
chagasi L. infantum
Repeat
Type BHU3c34 BHU3c32-6 BHU55c65 AG83c1 AG83c6 AG83c3
LV9-
11809
LV9-
11810 K26 LiJ23V3-1220
PKEDGHTQKNDGGG 0 1 1 1
PKEDGHTQNNDGGG 1 1 1
PKEDDHAHNDGGG 2 6 5 5 2 6 1
PKEDGHTQKNDGDG 3 2 2 1 5 2 22 3 3
PKEDDHAHNDGDG 4 3 2 3 2
PKEDDHAHNDGNG 5 1
PKEDDHAHNDGGC 6 1
PEEDGHTQKNDGDG 7 1
PKEDDHAHSDGGG 8 1 1
PKEDGHTQKNDGDA 9 1 1 1
PKEDGRTQKNDGDG 10 1 4 4
PKEDGRTQRNDGDG 11 1
PKEDGHTQKND 12 1
PKKDGHTQKNDGDG 13 1 1
PKEDDHTQKNDGDG 14 1 1
PKKDDHAHNDGDG 15 1
PKEDGHTQKNDDGG 16 1
PKEDGRTQKNDDGG 17 11
PKEDGRTQKNNGDG 18 1
PKEDGRTQKNDGGG 19 1
a LV9: MHOM/ET/67/L28/LV9 laboratory challenge strain.
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the HASPB C-terminal epitope was 2-fold greater when 10
9 pfu
were administered in the footpad instead of subcutaneously
(Figure 2C). Conversely, the response to the HASPB N-terminal
epitope and to KMP11 was selectively absent (Figure 2C).
Surprisingly, 10
8 pfu administered in the footpad gave the
broadest epitope coverage, although at the expense of potency
of individual epitopes (Figure 2D). Epitope selection was not
inﬂuenced to any appreciable extent by the use of a poly-
protein construct, because when KMP11 and HASPB were
independently expressed in Ad5 and used for vaccination,
similar epitopes were identiﬁed (data not shown). Thus, epi-
tope selection is subtly inﬂuenced by both dose and route of
administration, with combined responses of .2000 IFNc
1
CD8
1 T cells per 10
6spleen cells induced by single dose
vaccination.
We next evaluated the IgG subclass response in vaccinated
mice (Figure 2E–H), as indirect evidence for an underlying
CD4
1 T cell response. Footpad vaccination induced clear and
dose-dependent IgG1 and IgG2a responses, but we failed to
detect any response after subcutaneous vaccination, again
pointing to route of administration as a determinant of the
breadth of the host response. To establish whether differential
virus distribution might account for these diverse responses, we
evaluated the distribution of Ad5-GFP. After subcutaneous
injection, GFP
1 cells were readily detected in inguinal lymph
nodes (LNs). In contrast, after footpad injection, intense GFP
expression was observed in popliteal LNs, with GFP
1 cells also
detected in inguinal LNs and spleen (Supplementary Figure 1).
Although qualitative, these data suggest that footpad immuni-
zation may lead to greater viral infection and systemic spread.
To more readily monitor CD8
1 T cell responses, we ﬁne-
mapped the HASPB C terminus and the KMP11 epitopes
(data not shown). We identiﬁed only one candidate epitope in
each region, HASPBGGPKEGENL (where positions 1 and 2 derive
from repeat 17 and positions 3–9 are derived from the C
Figure 1. Epitope mapping of huKMP11_HASPB_consensus. A, Schematic diagram of huKMP11_HASPB_consensus. Each colored segment is
annotated for clarity. Black underscore bars indicate approximate positions of epitopes defined in (B). Subscript numbers refer to repeat number
(if appropriate) and respective AA position. B, Naive BALB/c mice were vaccinated subcutaneously with 10
8 pfu Ad5-KH. Peptide-specific responses to
huKMP11_HASPB_consensus were assessed by ELISPOTassay of pooled spleen cells. Data reflect one experiment of three performed that gave similar
results. C, Amino acid sequence of huKMP11_HASPB_consensus indicating TaV 2A sequence (red), regions containing dominant epitopes (underline) and
confirmed KMP11 and HASPB C terminus epitopes (blue).
856 d JID 2012:205 (1 March) d Maroof et alterminus) and KMP11HYEKFERMI (Figure 1C). Synthesized
single peptides recalled responses similar to the pools from
which they were identiﬁed (Figure 3A). The response to
HASPBGGPKEGENL was associated with a greater intensity of
IFNc secretion detected by ﬂow cytometry than that stimulated
by KMP11HYEKFERMI, and we conﬁrmed the poly-functionality
Figure 2. Response to vaccination with Ad5-KH is dose and route dependent. A–D, Naive BALB/c mice were vaccinated either subcutaneously (s.c.;
A, B) or into the footpad (f.p.; C, D) with 10
9 pfu (A, C)o r1 0
8 pfu (B,D)Ad5-KH. At 10days after vaccination splenocytes were prepared and restimulated
with pooled pepsets and assayed by IFNc ELISPOT assay. One of 2 experiments giving similar results is shown. E–H, IgG1 (E, F) and IgG2a (G, H)
responsestorecombinantKMP11(E,G)an dHA S PB( F,H)weredeterminedbyELISAinserum frommicevaccinatedwith10
9pfuf.p.(opencircle),10
9pfus.c
(open square),1 0
8 pfu f.p. (closed circle),o r1 0
8 pfu s.c. (closed triangle). Data represent mean 6 standard error of the mean derived from 5 mice per group.
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1 T cell response with respect
to IFNc,T N F ,I L - 2 ,a n dI L - 1 0( Figure 3B)[ 19].
CD8
1 T cell Response of L. donovani–Infected Mice to HASPB
and KMP11
We next asked whether L. donovani–infected mice had de-
tectable CD8
1 T cell responses to these antigens. However, no
CD8
1 T cell responses could be observed in infected mice
(Figure 4A). We studied 2 possible mechanisms that might
account for this lack of recognition. First, in the dominant
HASPBGGPKEGENL epitope, a HASPB repeat 17 provides po-
sition 1, whereas the LV9 challenge strain had a D for G
substitution at this position (Table 1). However, synthetic
peptides with either amino acid at position 1 had identical
activity (Figure 4B), and HASPBDGPKEGENL also failed to
stimulate CD8
1 T cells in infected mice (data not shown).
Second, to determine whether the lack of detectable response
might reﬂect clonal exhaustion/suppression because of anal-
ysis at a relatively late stage of infection [20], we tested mice
infected with L. donovani for only 7 days, when immune re-
sponses are relatively intact. These mice also failed to recognize
the respective peptides (Figure 4C; data not shown). These data
suggest that HASPB and KMP11 either fail to prime detectable
numbers of CD8
1 T cells or induce a very rapidly exhausted
response during normal infection.
Therapeutic Vaccination Using Ad5-KH
To evaluate the therapeutic efﬁcacy of Ad5-KH, mice infected
for 21 days were vaccinated and splenic parasite burden was
assessed 10 days later. In preliminary studies, we failed to
observe any signiﬁcant protection using Ad5-KH administered
subcutaneously (data not shown) and, therefore, focused on
vaccination with 10
9 pfu Ad5-KH administered in the footpad.
Splenic parasite burden in control nonvaccinated miceincreased
from day 21 to day 31 after infection, as expected [13, 21],
whereas in vaccinated mice parasite burden at day 31 was sig-
niﬁcantly lower (P , .001; n 5 23) (Figure 5A). Compared with
unvaccinated mice, the increase in spleen parasite burden from
day 21 to day 31 was inhibited by 66% 6 8% in mice vaccinated
with Ad5-KH (vs 29% 6 12% in Ad5-GFP vaccinated mice;
P 5 .013) (Figure 5B). With use of the lower value of the
95% conﬁdence interval of the mean parasite burden of un-
vaccinatedmiceasadeﬁning threshold,91%(21/23)ofAd5-KH
vaccinated mice were deﬁned as protected. Mice vaccinated with
Ad5-GFP had signiﬁcantly higher parasite burdens than those
vaccinated with Ad5-KH (P , .05) (Figure 5A), which were not
signiﬁcantly different from unvaccinated mice. However, Ad5-
GFP vaccinated mice did show a trend indicative of a degree of
nonspeciﬁc protection compared with unvaccinated mice, at
least in some mice (65% responders; P , .03 vs. Ad5-KH vac-
cinated) (Figure 5A). Thus, Ad5-KH constitutes an effective
therapeuticintervention inthisexperimental model ofinfection,
with a component of protection likely being attributable to
nonspeciﬁc effects of the viral vector.
We then asked whether therapeutic vaccination stimulated
HASPB- and/or KMP11-speciﬁc CD8
1 T cells in infected mice.
Similartononvaccinatedcontrols,infectedmicevaccinatedwith
Ad5-GFP did not respond to any peptides tested, indicating that
nonspeciﬁc immune stimulation could not recover potentially
underlying CD8
1 T cell responses (Figure 6A and Figure 4A). In
contrast, Ad5-KH–vaccinated mice responded to HASPB with
the same breadth of response seen in uninfected, vaccinated
Figure 3. Fine mapping of KMP11 and HASPB epitopes. A, Naive BALB/c mice were vaccinated in the footpad with 10
9 pfu Ad5-KH and 10 days later
splenocytes were restimulated with either the pooled pepsets from which the epitope was derived or synthetic peptides corresponding to predicted
epitopes. After 3 h, Brefeldin A was added for an additional 4 h. Cells were surface-stained for CD3 and CD8 and then stained for intracellular IFNc and
IL-10. The percentage of cytokine positive cells is indicated in each quadrant. B, CD8
1 T cells from mice vaccinated as above were restimulated with
HASPB peptide, surface-stained for CD3 and CD8, and stained for intracellular cytokines. HASPB-specific CD8
1 T cells were initially separated into
IFNc
1TNF
-or IFNc
1TNF
1 subsets and then further sub-divided on the basis of IL-2 and IL-10 production. Pie charts reflect the relative contribution
of the different cytokine-producing CD8
1 Tcell populations and percentage of each population is indicated. Data are mean 6 standard error of the
mean (5 mice).
858 d JID 2012:205 (1 March) d Maroof et almice (Figure 6A and Figure 2C), with an estimated 200 000
IFNc
1 CD8
1 T cells per infected spleen. As also noted in un-
infected mice, we detected no response to KMP11 in vaccinated
infected mice by ELISPOT (Figure 6A). However, by in-
tracellular ﬂow cytometry, a signiﬁcant although weak response
against KMPHYEKFERMI could be identiﬁed in vaccinated mice
(Figure 6B). This equated to 100 000KMPHYEKFERMI-speciﬁc
IFNc
1 CD8
1 T cells per spleen, compared with 400 000IFNc
1
CD8
1 T cells responding to HASPBGGPKEGENL (Figure 6C). The
discrepancy between the magnitude of the response determined
by ELISPOT and ﬂow cytometry is likely attributable to dif-
ferent thresholds for scoring positive responses (electronic
gating vs. manual scoring based on spot size).
The poor recognition of HASPB and KMP11 observed in
nonvaccinated L. donovani–infected mice did not extend to the
CD4
1 T cell and B cell compartment, because IgG1 and IgG2a
responses to both antigens were readily detectable. These re-
sponses were boosted by therapeutic vaccination with Ad5-KH
but not by Ad5-GFP (Figure 6D–G). Together, these data in-
dicate that successful therapeutic vaccination with Ad5-KH was
accompanied by the appearance of detectable vaccine antigen-
speciﬁc CD8
1 T cell responses, with bias toward HASPB and
boosting of antibody responses to both vaccine antigens.
DISCUSSION
This study demonstrates that an adenovirus-based vaccine can
provide signiﬁcant therapeutic effects in mice infected with
L. donovani. With the caveat of the sensitivity of in vitro recall
assays, both of HASPB and KMP11 appear to be examples of
cryptic antigens in terms of CD8
1 T cell recognition (ie, they
failed to stimulate detectable responses after infection, but are
nevertheless immunogenic when used for vaccination) [23].
Our strategy to develop a therapeutic vaccine was driven by
a 5-point product proﬁle. First, we sought to show efﬁcacy in
a selected animal model. We chose inhibition of spleen parasite
growth in mice, because this organ fails to spontaneously clear
infection and is relatively refractory to drug treatment (reviewed
in [24]). Furthermore, we studied the impact of therapeutic
vaccination when parasite burden was increasing at its maximal
rate and when tissue breakdown and immunosuppression
were established [14, 20, 25]. Although it is unlikely that
a therapeutic vaccine would be used alone [11], we set our
criterion for success as inhibition of parasite growth of
50%. This level of response equates favorably to that seen
following single dose therapy using 4 mg/kg Ambisome [26]o r
administration of sodium stibogluconate [27], although better
responses are achievable with longer chemotherapy [26, 28].
Second, for clinical practicality, we aimed for efﬁcacy using
a single vaccination. Adenoviral vectors have been reported to
provide single dose protection against Plasmodium berghei in
Figure 5. Therapeutic vaccination using Ad5-KH. BALB/c mice were
infected with Leishmania donovani and at day 21 after infection,
immunized in the footpad with 10
9 pfu Ad5-KH. A, Parasite burden was
evaluated at day 31 from Giemsa-stained impression smears and is
expressed in Leishman Donovan Units (LDU; [13]). Data are pooled from
three independent experiments (20–23 mice per group). Mean 6
standard error of the mean parasite burden is indicated. Significant
differences in parasite load as determined by ANOVA are shown in
horizontal bars. B, Percentage inhibition of parasite growth at day 31 was
calculated for mice vaccinated with Ad5-KH and Ad5-GFP, according to
the formula: (LDU d31 unvaccinated - LDU d21) - (LDU d31 vaccinated -
LDU d21)/(LDU d31 unvaccinated - LDU d21) 3 100 [22]. Data were
analysed by Student's t test.
Figure 4. HASPB- and KMP11-specific CD8
1 Tcells are not detectable
in Leishmania donovani–infected mice. A, BALB/c mice were infected
with 3 3 10
7 L. donovani amastigotes and at day 31 after infection,
splenic CD8
1 Tcells were analyzed for responses to huKMP11_HASPB_
consensus using pooled pepsets and ELISPOT assay. B, CD8
1 T cell
responses in day 21–infected BALB/c mice immunized with Ad5-KH
were evaluated for IFNc production by flow cytometry after restimulation
with GGPKEGENL (contained in Ad5-KH) or DGPKEGENL (as found in
the LV9 challenge strain). C, BALB/c mice infected for 7 days with
L. donovani were tested for CD8
1 Tcell responses using KMP11HYEKFERMI
and HASPBGGPKEGENL.
Therapeutic Vaccine for Leishmaniasis d JID 2012:205 (1 March) d 859Figure 6. ImmuneresponsesinducedbyvaccinationwithAd5-KHinLeishmaniadonovani–infectedmice.A,CD8
1 TcellresponsesevaluatedbyELISPOT
in mice vaccinated with Ad5-GFP (top) or Ad5-KH (bottom). B and C, Peptide-specific IFNc responses to KMP11HYEKFERMI and HASPBGGPKEGENL were
evaluated by flow cytometry and presented as frequency of responding CD8
1 T cells (B) and as absolute number of peptide specific CD8
1 T cells per
spleen(C).Valuesof individual miceareplotted. Data arederivedfromoneof the3 experiments includedin Figure 5 (inwhich inhibition ofparasite growth
induced by Ad5-KH was 96% 6 6% and by Ad5-GFP was 56% 6 10%; n 5 8; P ,.01). D–G. IgG1 (D and E) and IgG2a (F and G) antibody responses to
KMP11 (D and F) andHASPB (E and G) were determined by ELISAusing serum from unvaccinated infected mice (circles)and infected mice vaccinated with
Ad5-GFP (squares) or Ad5-KH (triangles). Data represent mean 6 standard error of the mean derived from 6–8 mice per group from one experiment.
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regimens, although greater efﬁcacy might be anticipated
[30–32]. Third, we chose a delivery system that would beneﬁt
from inherent adjuvant activity, because a degree of protection
due to nonspeciﬁc proinﬂammatory responses is well
documented [33–36]. In this respect, marked similarities in
host gene expression signatures induced by adenovirus [37]
and L. donovani [38] have been noted. It remains to be
determined whether this adjuvant effect operates directly [38]
or is secondary to a reduction in parasite burden (as might
also be anticipated in sequential chemo-immunotherapy).
Fourth, with limited resources for clinical trials, we sought to
develop a vaccine based on a platform with established safety
and immunogenicity data. Adenoviruses are widely accepted
as one of the most potent means to induce CD8
1 T cell
priming, along with CD4
1 T cell and antibody responses [40].
Although some caution remains about the use of Ad5 in
humans [41], new generation simian adenoviruses appear to
be safe and to circumvent existing anti-Ad5 immunity [42].
Fifth, adenovirus can be stored in a thermostable manner
[43], facilitating delivery in countries where the disease is
endemic.
The selection of HASPB was based on prophylactic vaccina-
tion studies indicating good protection associated with the de-
velopment of CD8
1 T-cell responses in mice [13, 21]a n d
immunogenicity in dogs [44]. Although HASPB in our labora-
tory strain of L. donovani has multiple identical repeats, ﬁeld
isolates show extensive divergence in repeat sequence and ar-
rangement. Such repeat diversity may suggest immune selective
pressure [45]. We therefore developed a synthetic HASPB gene
in which the sequence and composition of 10 repeat units was
chosen (1) to preserve the relative order of repeats that were
present in .1 clinical isolate, (2) to conserve some of the repeat
reiteration found in natural isolates (eg, strings of repeat 2), and
(3) to maintain the overall protein length to that found in
natural isolates. Our data showing that, at least in BALB/c mice,
CD8
1 T cell recognition is largely focused on the N and C
termini of HASPB and that HASPB is weakly if at all recog-
nized by CD8
1 T cells during normal infection argue that re-
peat variation may not be under CD8
1 T cell selective immune
pressure. The IFNc
1CD8
1 T cell responses against HASPB in-
duced in infected mice by vaccination (400,000 sfc per spleen
for HASPBGGPKEGENL alone) were also similar or better than
those reported for single dose vaccination in other systems, in-
cluding Ad5-L. donovani A2 [29, 46]. Neither published data
nor the current study have directly addressed whether CD8
1 T
cells alone are sufﬁcient for protection, and indeed antibody
and CD4
1 T cell responses are present under all conditions
examined. Nevertheless, it is notable that adoptive transfer
of only 10
6 CD8
1 T cells recognizing an ovalbumin epitope
expressed in transgenic L. donovani afforded therapeutic
protection in a similar model [47].
KMP11 has been shown to be protective in murine L. dono-
vani infection when administered as a DNA vaccine [48], and
multiple human epitopes have been mapped [49], suggesting
that it would be immunogenic in humans. Under the immu-
nization regimen chosen for studies of protection here, we did
not observe an appreciable ELISPOT response to KMP11 after
vaccination of either uninfected or infected wild-type mice,
although a weak response was detectable by ﬂow cytometry.
This limited recognition was vaccine dose- and route-
dependent, arguing against problems in KMP11 recognition
because of expression as a self-cleaving polyprotein or inherent
lack of immunogenicity. The basis for this observation is under
further study. Nevertheless, our data clearly demonstrate how
subtle alterations in vaccine delivery alter epitope selection
and indirectly highlight the difﬁculties in extrapolating from
epitope recognition in vaccinated mice to vaccinated humans.
Finally, although CD8
1 T cell responses to HASPB and
KMP11 have yet to be studied in patients with any form of
leishmaniasis, it is of interest that neither HASPB nor KMP11
have proved to be particularly good at inducing recall CD4
1 T
cells responses in patients recovered from HVL [50], although
HASPB antibody responses have been shown to have diagnostic
potential [51]. Our data suggest that there may be no a priori
requirement for an antigen to be well recognized during
natural infection for it to be effective when used for thera-
peutic (and perhaps prophylactic) vaccination. Only clinical
trial will determine whether huKMP11_HASPB_consensus
expressed in an adenoviral vector is immunogenic and effec-
tive as a tool for combined immunotherapy against HVL or
other forms of leishmaniasis.
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